Hyloris Ramps Up Product Expansion With New Idiopathic Rhinitis Spray
Hyloris Plans Four New Candidate Product Additions On Average Per Year From 2022
Executive Summary
Hyloris Pharmaceuticals’ new idiopathic rhinitis treatment sets it on track to achieve its target of around 30 portfolio assets by the end of 2024.
You may also be interested in...
Hyloris On Track To Meet 2024 Target During Half-Year Update
Hyloris CEO Stijn Van Rompay said the firm is on track to meet its target of 30 portfolio products by 2024, delivering a confident Q2 half-year update despite some pushback from the US Food and Drug Administration on its Maxigesic IV compound.
Hyloris Raises €15m In Private Equity Offering
Value-added medicines firm Hyloris has raised €15m from new and existing investors through a private equity offering of nearly one million new shares.
Neuraxpharm’s New Belgian Division Advances European Expansion Strategy
Neuraxpharm continues its European expansion with a new Brussels-based Belgian unit to be headed by country manager Pierre-Hervé Brun. The announcement adds to the more than 20 European countries where the company is recognized and established.